1-[3-(4-Morpholinyl)propyl]-4-(3-methylthio phenyl)-5-(pyridin-4-yl)imidazole | 165806-21-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-[3-(4-Morpholinyl)propyl]-4-(3-methylthio phenyl)-5-(pyridin-4-yl)imidazole
• 英文别名: 1-[3-(4-morpholinyl)propyl]-4-(3-methylthiophenyl)-5-(4-pyridyl)imidazole；4-[3-[4-(3-Methylsulfanylphenyl)-5-pyridin-4-ylimidazol-1-yl]propyl]morpholine
• CAS: 165806-21-3
• 化学式: C₂₂H₂₆N₄OS
• 分子量: 394.541
• InChiKey: MFWRRYPZURQIQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  68.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[3-(4-Morpholinyl)propyl]-4-(3-methylthio phenyl)-5-(pyridin-4-yl)imidazole 在 dipotassium peroxodisulfate 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 16.0h， 以42%的产率得到1-[3-(4-Morpholinyl)propyl]-4-(3-methylsulfinylphenyl)-5-(pyridin-4-yl)imidazole
  参考文献：
  名称：

  Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties

  摘要：

  这项发明涉及一类新型的甲酰胺化合物及其制备方法，可用于制备具有多种治疗性能的三取代咪唑。

  公开号：

  EP1227091A3
• 作为产物：
  描述：

  N-(3-氨丙基)吗啉 在 1,5,7-三氮杂双环[4.4.0]癸-5-烯 、 magnesium sulfate 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 34.0h， 生成 1-[3-(4-Morpholinyl)propyl]-4-(3-methylthio phenyl)-5-(pyridin-4-yl)imidazole
  参考文献：
  名称：

  Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase

  摘要：

  Members of three classes of pyridinylimidazoles bind with varying affinities to CSBP (p38) kinase which is a member of a stress-induced signal transduction pathway. Based upon SAR and protein homology modeling, the pharmacophore and three potential modes of binding to the enzyme are presented. For a subset of pyridinylimidazoles, binding is shown to correlate with inhibition of CSBP kinase activity, whereas no significant inhibition of PKA, PKC alpha and ERK kinase activity is observed. Copyright (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(96)00212-x

文献信息

• Imine intermediates for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1229035A1

  公开（公告）日：2002-08-07

  The invention relates to a novel group of iminc compounds and a process for their preparation, useful in the preparation of tri-substituted imadazoles having multiple therapeutic properties.

  这项发明涉及一类新型的iminc化合物及其制备方法，可用于制备具有多种治疗性能的三取代咪唑。
• Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties
  申请人：SmithKline Beecham Corporation

  公开号：EP1227092A3

  公开（公告）日：2002-08-07

  The invention relates to a novel group of isonitrile compounds and a process for their preparation, useful in the preparation of tri-substituted imadazoles having multiple therapeutic properties.

  这项发明涉及一类新型异腈化合物及其制备方法，可用于制备具有多种治疗性能的三取代咪唑。
• Novel compounds
  申请人：SmithKline Beecham Corporation

  公开号：US20020188122A1

  公开（公告）日：2002-12-12

  Novel 1, 4, 5- substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.

  小说1、4、5-取代咪唑化合物和组合物，用于作为细胞因子抑制剂的治疗。
• Process for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1291346A1

  公开（公告）日：2003-03-12

  Novel 1,4,5- substituted imidazole compounds and compositions for use in therapy.

  用于治疗的新型 1,4,5-取代咪唑化合物和组合物。
• Methods for promoting survival of transplanted tissues and cells
  申请人：Johnson & Johnson Vision Care, Inc.

  公开号：EP1676574A2

  公开（公告）日：2006-07-05

  Methods for enhancing the survival of a cell, tissue, or organ transplanted into a recipient comprising contacting the cell, tissue, or organ graft with an agent that decreases the rate of coagulation on the transplanted cell, tissue or organ are disclosed. The agent is one that acts by reducing the amount or activity of tissue factor (TF) on the donor tissue, such as a p38 MAPK inhibitor, a JNK inhibitor, a p38 MAPK/JNK dual inhibitor and a TF antagonist. Cells, tissues and organs treated with those agents are also disclosed.

  本发明公开了提高移植到受者体内的细胞、组织或器官存活率的方法，该方法包括使细胞、组织或器官移植体与一种能降低移植细胞、组织或器官凝血率的药剂接触。这种药剂通过减少供体组织上组织因子（TF）的数量或活性发挥作用，如 p38 MAPK 抑制剂、JNK 抑制剂、p38 MAPK/JNK 双抑制剂和 TF 拮抗剂。还公开了用这些制剂处理的细胞、组织和器官。